COMPANY:

Inocras

"Getlabs...has joined forces with Inocras...that empowers patients with critical genetic insights for cancer and rare diseases...Inocras provides whole genome sequencing tests, which deliver patients deep insights into their cancer and rare disease by providing comprehensive and detailed analyses of an individual's genetic composition."

"Inocras...proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively."

"Inocras...is making an impact at the American Association for Cancer Research (AACR) 2024 annual meeting from April 5 to 10, held in San Diego. This event premieres Inocras's substantial research and pioneering innovation in cancer diagnostics, driven by cutting-edge machine learning technology...In their poster presentation, Inocras showcases the refined approach of machine learning in examining whole-genome sequencing (WGS) data from tissues preserved in formalin-fixed paraffin-embedded (FFPE) samples, a common preservation technique in clinical environments...The study unveils a cutting-edge machine learning strategy to accurately identify genetic changes caused by FFPE processing....this research sheds light on specific FFPE-induced genetic alteration patterns, such as cytosine deamination and unique mutational signatures, while proving its efficacy in assessing vital cancer and genomic metrics, including homologous recombination deficiency (HRD)..."